AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
clinicaltrialsarena4d
Eli Lilly’s three-year Ebglyss study leaves 50% of AD patients with clear skin
Eli Lilly’s Ebglyss (lebrikizumab-lbkz ... Bambusa Therapeutics has announced the dosing of its first healthy volunteers as part of a Phase I trial on its half-life extended bispecific antibody ...